What Fueled The Previous Growth In The Pharyngitis Treatment Market?
The pharyngitis treatment market has seen considerable growth due to a variety of factors.
• In recent times, the pharyngitis treatment sector has seen a consistent growth pattern. The market is projected to expand from $2.27 billion in 2024 to a substantial $2.37 billion in 2025, with an impressive Compound Annual Growth Rate (CAGR) of 4.5%.
The sizeable growth in the historical period can be credited to an increasing occurrence of flu, high prevalence of pharyngitis, heightened awareness about the condition, improved healthcare access, and growing disposable income levels.
How Does the Forecast Look for the Pharyngitis Treatment Market?
The pharyngitis treatment market is expected to maintain its strong growth trajectory in upcoming years.
• There is a strong projection for the pharyngitis treatment market to experience substantial growth in the coming years. Its value is anticipated to hit $2.99 billion by 2029, at a compound annual growth rate (CAGR) of 6.0%.
The expansion during the forecasted period can be credited to factors like the use of rapid point-of-care tests, the growing demand for personalized medicine, an increase in antibiotic resistance, and the growing emphasis on hand hygiene. The period is also likely to see significant trends including advancements in the research and development of therapies for pharyngitis, the introduction of digital health technologies, and the integration of telehealth.
What Are The Leading Drivers Of Growth In The Pharyngitis Treatment Market?
A surge in strep throat cases is poised to drive the growth of the pharyngitis treatment market. Strep throat is an infectious bacterial ailment predominantly affecting the throat and tonsils. Swift and effective treatment of strep throat using antibiotics can reduce symptoms, stave off complications, and lower the risk of transferring the infection to others. Data from the Centers for Disease Control and Prevention in June 2022 indicated that an estimated 14,000 to 25,000 invasive group A strep disease cases occur in the United States annually. Strep illnesses also account for approximately 5.2 million outpatient visits and 2.8 million annual antibiotic prescriptions. Consequently, strep throat's escalating transmission bolsters the pharyngitis treatment market. The pharyngitis treatment market is also expected to be driven by an increase in influenza cases. Influenza, or the flu, is an infectious respiratory disease caused by influenza viruses. Pharyngitis treatment, typically used to manage influenza, mitigates the symptoms, which include inflammation or irritation, and prevents complications like pneumonia and bronchitis. For example, the European Centre for Disease Prevention and Control (ECDC) reported in July 2023 that 42% of influenza specimens tested positive in the 51st week of 2022 during the 2022/2023 flu season in the EU/EEA. Positivity hovered around 28% from the 5th to the 12th week of 2023. Therefore, the increasing prevalence of influenza is fuelling the expansion of the pharyngitis treatment market.
How Are The Segments Defined Within The Global Pharyngitis Treatment Market?
The pharyngitis treatment market covered in this report is segmented –
1) By Drug Class: Beta Lactams, Macrolides, Cephalosporins, Fluoroquinolones, Tetracycline, Other Drug Classes
2) By Source of Infection: Viral, Bacterial
3) By Modes Of Delivery: Oral, Intravenous, Intramuscular, Other Modes Of Delivery
4) By End-Users: Hospitals, Homecare, Specialty Centers, Other End-Users
Subsegments:
1) By Beta Lactams: Penicillins, Amoxicillin, Ampicillin
2) By Macrolides: Erythromycin, Azithromycin, Clarithromycin
3) By Cephalosporins: Cefuroxime, Ceftriaxone, Cefdinir
4) By Fluoroquinolones: Ciprofloxacin, Levofloxacin, Moxifloxacin
5) By Tetracycline: Doxycycline, Minocycline, Tetracycline
6) By Other Drug Classes: Clindamycin, Sulfonamides, Carbapenems
Pre-Book The Pharyngitis Treatment Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
What Trends Are Shaping The Pharyngitis Treatment Market?
Leading firms in the pharyngitis treatment market are turning their focus towards creating advanced products like oral monotherapy, intending to improve patient compliance and deliver efficient, handy treatment alternatives. Oral monotherapy denotes the utilization of an individual medicine taken orally to mitigate a particular disorder or disease. This therapeutic approach implies administration of a single therapeutic agent instead of multiple combined treatments to achieve the therapy's anticipated outcome. For example, in December 2023, The FDA granted approval to Novartis AG, a pharmaceutical corporation from Switzerland, for Fabhalta (iptacopan), marking it as the inaugural oral monotherapy for adult patients suffering from paroxysmal nocturnal hemoglobinuria (PNH). This achievement on [date] signifies a notable evolution by furnishing a novel treatment substitute that boosts hemoglobin levels, thereby abrogating the requirement for blood transfusions.
Who Are the Key Players In The Pharyngitis Treatment Market?
Major companies operating in the pharyngitis treatment market are:
• Pfizer Inc.
• GlaxoSmithKline PLC
• Genentech Inc.
• Pliva Hrvatska D.o.o.
• Viatris Inc.
• Teva Pharmaceutical Industries Ltd.
• AbbVie Inc.
• Medtronic PLC
• Takeda Pharmaceutical Company Limited
• Eli Lilly and Company
• Gilead Sciences Inc.
• Amgen Inc.
• Boehringer Ingelheim International GmbH
• Viatris Inc.
• Teva Pharmaceutical Industries Ltd.
• Fresenius Kabi AG
• Bausch Health Companies Inc.
• Sun Pharmaceutical Industries Ltd.
• Dr. Reddy's Laboratories Ltd.
• Cipla Limited
• Hikma Pharmaceuticals PLC
• Lupin Limited
• Pliva Hrvatska D.o.o.
• LivaNova PLC
• Genentech Inc.
What Is The Most Dominant Region In The Pharyngitis Treatment Market?
North America was the largest region in the pharyngitis treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in pharyngitis treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
